drugset / Trial / NCT06026410
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Timeline
- Start
- 2023-10-18
- Primary completion
- 2027-01
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Darlifarnib | Unknown | — | Oral |
| Background | Adagrasib | Small molecule | — | Oral |